1. Fraisinib: a calixpyrrole derivative reducing A549 cell-derived NSCLC tumor in vivo acts as a ligand of the glycine-tRNA synthase, a new molecular target in oncology
    Iméne Ben Toumia et al, 2024, Frontiers in Pharmacology CrossRef
  2. Exploring the Molecular Players behind the Potentiation of Chemotherapy Effects by Durvalumab in Lung Adenocarcinoma Cell Lines
    Marika Saar et al, 2023, Pharmaceutics CrossRef
  3. Interaction between NSCLC Cells, CD8+ T-Cells and Immune Checkpoint Inhibitors Potentiates Coagulation and Promotes Metabolic Remodeling—New Cues on CAT-VTE
    Catarina Freitas-Dias et al, 2024, Cells CrossRef